ArticleVeterinary research2026
WH01-3A: a DIVA-compliant, ApxIA, ApxIIA, and ApxIIIA expressing Actinobacillus pleuropneumoniae live attenuated vaccine strain that protects mice and pigs against homologous and heterologous serovars.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia, a major economic burden to the worldwide swine industry. Many available vaccines protect against one or a few of the 19 serovars known. Live attenuated vaccines can potentially protect against many different serovars. In this study, the highly virulent parental A. pleuropneumoniae serovar 1 strain WH01 was used to construct WH01-3A, expressing nontoxic (nonacylated) versions of the three major toxin antigens ApxIA, ApxIIA, and ApxIIIA. In addition, the vivo-induced toxin ApxIVA was deleted, enabling use in a differentiation of vaccinated from infected animals (DIVA) strategy. Compared with WH01, the virulence of WH01-3A in mice was significantly reduced, and, when used as a live attenuated vaccine, WH01-3A protected 87.5%, 75%, and 87.5% animals against A. pleuropneumoniae challenge with serovars 1, 5, and 15, respectively. Pigs immunized with up to 5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.